Unknown

Dataset Information

A phase III, single-arm, 6-month trial of a wide-dose range oral testosterone undecanoate product.


ABSTRACT:

Background

Oral testosterone undecanoate (TU) formulations may provide effective, safe, and easily titratable testosterone replacement therapy.

Objective

Demonstrate efficacy and safety of a novel oral TU formulation.

Design

An open-label, single-arm, multi-center trial treated 155 hypogonadal men for 180 days. Treatment began at 200 mg TU twice daily with meals; doses were titrated over two 28-day cycles to between 100 and 800 mg TU daily, measuring average testosterone (T Cavg) after 90 days. Ambulatory blood pressure monitoring (ABPM) occurred at baseline, 120, and 180 days.

Methods

Titrations used a randomized blood sample taken 3-, 4-, or 5-h post-morning dose. Outcomes used sodium fluoride/ethylenediaminetetraacetate plasma testosterone (T) val

SUBMITTER: Bernstein JS 

PROVIDER: S-EPMC11008350 | biostudies-literature | 2024 Jan-Dec

REPOSITORIES: biostudies-literature